OTCM
IBOGF
Market cap31kUSD
Oct 07, Last price
0.00USD
1D
0.00%
1Q
-99.64%
IPO
-99.87%
Name
Universal Ibogaine Inc
Chart & performance
P/E
—
P/S
0.04
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1m
Net income
-10m
L+171.41%
CFO
-4m
L+33.34%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Universal Ibogaine Inc., a life sciences enterprise, focuses on developing, acquiring, and operating addiction treatment centers across Canada. The company is additionally preparing to launch clinical trials aimed at researching ibogaine's potential therapeutic applications for addiction. Its principal corporate offices are based in Calgary, Canada.
Headquarters & legal address
600-815 8 AVE
CALGARY, AB T2P 3P2
CA
CALGARY, AB T2P 3P2
CA
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2022‑07 | 2021‑07 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||